AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance

AbbVie (NYSE: ABBV) reported Q3 EPS of $3.00, $0.08 better than the analyst estimate of $2.92. Revenue for the quarter came in at $14.46 billion versus the consensus estimate of $14.28 billion.

GUIDANCE:

AbbVie sees FY2024 EPS of $10.90-$10.94, versus the consensus of $10.85.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30
• Shein targets $26-27 billion valuation in Hong Kong IPO - report